That’s a big positive for companies like biotech rock star Gilead Sciences (GILD). The maker of hepatitis C drugs is expected to reveal an eye-popping 300% surge in earnings per share when it reports results on Tuesday.
More traditional pharmaceutical companies like Merck (MRK) should also benefit from the demographic shift. Merck is expected to post annual sales of $42 billion when it reports on Friday, a slight decrease from 2013.
Related: US economy misses the market at the end of 2014
Cheap oil = more manufacturing jobs: Whitney, who back in 2007 presciently predicted Citigroup (C) was in serious financial trouble, believes the labor market will get a shot in the arm from the manufacturing sector. Her thinking is that relatively cheap energy costs in the U.S. will prompt manufacturers to bring more jobs back to America.
–
Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.
Factset: FactSet Research Systems Inc. 2015. All rights reserved.
Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.
